Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Non-Small Cell Lunch Cancer × Carboplatin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 695 Lung Neoplasms 301 Ovarian Neoplasms 291 Breast Neoplasms 243 Fallopian Tube Neoplasms 145 Small Cell Lung Carcinoma 127 Triple Negative Breast Neoplasms 125 Neoplasms 123 Squamous Cell Carcinoma of Head and Neck 110 Carcinoma, Ovarian Epithelial 107 Neoplasm Metastasis 75 Head and Neck Neoplasms 69 Endometrial Neoplasms 65 Uterine Cervical Neoplasms 61 Esophageal Neoplasms 61 Adenocarcinoma of Lung 61 Central Nervous System Neoplasms 47 Brain Neoplasms 46 Recurrence 45 Carcinoma 43 Prostatic Neoplasms 42 Neuroblastoma 42 Lymphoma, Large B-Cell, Diffuse 42 Parkinson Disease 4, Autosomal Dominant Lewy Body 39 Urinary Bladder Neoplasms 37 Esophageal Squamous Cell Carcinoma 36 Lymphoma 34 Carcinoma, Squamous Cell 32 Stomach Neoplasms 31 Melanoma 29

Interventions

Paclitaxel 1 NVP-BKM120 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01820325 2018-10-11

BASALT-2

Novartis

Phase 1 Terminated

Non-Small Cell Lunch Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡